Shin Nippon Biomedical Laboratories (SNBL)
SNBL Ltd. is a company dedicated to supporting drug discovery and medical technology improvements with a mission to liberate humanity from pain. With over 60 years of experience, it offers high-quality services and solutions in the life sciences sector, including contract research organization (CRO) services, translational research, and environmentally conscious Medipolis projects. The company emphasizes environmental, social, and governance (ESG) principles, and aims to create happiness and value for stakeholders through its innovative and global operations.
Industries
Nr. of Employees
Very Large (1000+)
Shin Nippon Biomedical Laboratories (SNBL)
Products
Intranasal formulation and delivery platform
Platform technology for development of intranasal formulations and delivery methods used in translational research and early drug development.
Intranasal formulation and delivery platform
Platform technology for development of intranasal formulations and delivery methods used in translational research and early drug development.
Services
Integrated CRO services covering nonclinical safety studies, bioanalysis, pathology, and clinical trial conduct for drug development programs.
Collaborative R&D to advance discovery-stage assets and application of an intranasal delivery platform to translational programs.
Laboratory services for quantitative drug concentration analysis and nonclinical/clinical pharmacokinetic studies.
Pathology assessment and histological analysis of study samples performed in GLP-certified pathology laboratories and branches.
Provision and management of NHP breeding facilities and integration of NHPs into nonclinical testing workflows.
Preparation and support of standardized nonclinical data sets for regulatory submissions (SEND support).
Integrated CRO services covering nonclinical safety studies, bioanalysis, pathology, and clinical trial conduct for drug development programs.
Collaborative R&D to advance discovery-stage assets and application of an intranasal delivery platform to translational programs.
Laboratory services for quantitative drug concentration analysis and nonclinical/clinical pharmacokinetic studies.
Pathology assessment and histological analysis of study samples performed in GLP-certified pathology laboratories and branches.
Provision and management of NHP breeding facilities and integration of NHPs into nonclinical testing workflows.
Preparation and support of standardized nonclinical data sets for regulatory submissions (SEND support).
Expertise Areas
- Nonclinical safety assessment
- Clinical trial management (Phase I–III)
- Bioanalytical services and pharmacokinetics
- Translational research and formulation development
Key Technologies
- GLP-compliant toxicology studies
- AAALAC-accredited animal care
- Nonclinical and clinical bioanalysis (PK assays)
- Histopathology and tissue evaluation
News & Updates
The company's chairman and president Ryoichi Nagata appeared on Nikkei CNBC's 'Top Interview' program, discussing the company's vision and activities.
Official notice for the 52nd Annual Shareholders' Meeting scheduled for June 5, 2025.
The company's chairman and president Ryoichi Nagata appeared on Nikkei CNBC's 'Top Interview' program, discussing the company's vision and activities.
Official notice for the 52nd Annual Shareholders' Meeting scheduled for June 5, 2025.